Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1896)	12/12/2007 6:16:22 AM
From: kenhott	Read Replies (1) \| Respond to of 2240

I have to find some time to listen to the conference call. I would guess nothing really juicy good (or really juicy bad) came out of the call from the stock price. It is 2nd line melanoma and it is a drug that doesn't act like chemo. So the miss, as expected, may not be as FDA deadly as people are feeling. Looks like MEDX will file and they will definitely get a FDA committee. It is not going to be the FDA being dense but the science that will show at the end of the day. MEDX didn't give much of a bone with this PR.